Most investors tend to think that hedge funds and other asset managers are worthless, as they cannot beat even simple index fund portfolios. In fact, most people expect hedge funds to compete with and outperform the bull market that we have witnessed in recent years. However, hedge funds are generally partially hedged and aim at […]
Quantum Computing: Is IonQ Worth The Leap? forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.
Dem Megadonors, Officials Financially Tied to Electric Bus Company Boosted by Biden
Dem-linked investment firms pumped millions into Proterra before White House spotlighted green company Nicholas and Susan Pritzker in 2013 / Getty Images Collin Anderson and Matthew Foldi • May 5, 2021 5:00 am
Energy secretary Jennifer Granholm is not the only prominent Democrat with financial ties to an electric bus company repeatedly boosted by the Biden administration, documents reviewed by the
Washington Free Beacon show.
Nicholas and Joby Pritzker members of Illinois Democratic governor J.B. Pritzker s megadonor family own nearly 12 million shares of ArcLight through their venture capital fund, Tao Capital. ArcLight in January announced a $1.6 billion merger with Proterra, which will see the electric vehicle manufacturer go public in 2021. Granholm served on Proterra s board for nearly four years and still holds up to $5 million in company stock.
Ultivue Announces $50M Financing Round
on April 28 2021 12:07 AM
CAMBRIDGE, Mass. (BUSINESS WIRE) Ultivue, a leader in advancing precision medicine solutions through a unique approach that combines multiplex biomarker analysis with same slide traditional H&E for tissue phenotyping, today announced the completion of a $50 million Series D round of financing. New investors include Ally Bridge Group, Pura Vida Investments and Tao Capital Partners. Previous venture investors in Ultivue who also participated in the financing include ARCH Ventures, Northpond Ventures and Applied Ventures, LLC.
This additional funding will help Ultivue strengthen its position in the market, deliver innovative solutions to address the dynamic nature of tumor biology from precious tissue samples and to provide researchers and pathologists with the ability to fully realize the potential of tissue biomarkers within digital pathology workflows.